DOJ Updated Emergency Scheduling for Opioid Substances

The Department of Justice issued new guidance for four opioid substances to target dangerous concentrations.

Updated on Oct. 10, 2026 in Substance Abuse

Bold flat-color editorial illustration depicting three glass laboratory beakers of varying concentration levels, conveying federal drug policy updates. — The Department of Justice issued new emergency scheduling guidance for four opioid substances, aiming to regulate high-concentration products while exempting natural botanical trace amounts. AI Illustration. Upload story photo >

Live Poll

Should the government regulate botanical products containing trace amounts of synthetic opioid substances?

The Department of Justice updated emergency scheduling actions for 7-hydroxymitragynine, mitragynine pseudoindoxyl, MGM-15, and MGM-16. These measures incorporate updated scientific recommendations from the HHS to target synthetic opioid products.

Why it matters

The actions aim to protect communities from dangerous and addictive opioids by distinguishing between trace botanical amounts and intentionally enhanced, high-concentration products.

Federal controls apply when solids exceed 1 milligram per gram or liquids exceed 1 milligram per milliliter. Regulations also trigger if the ratio of mitragynine to 7-OH or MGPI is less than 100 to 1.

The players

Department of Justice

The federal executive department responsible for the enforcement of federal law and administration of justice in the United States.

Drug Enforcement Administration

The federal law enforcement agency tasked with combating drug smuggling and use within the United States.

Department of Health and Human Services

The federal agency that provides the scientific and medical recommendations necessary for the scheduling of controlled substances.

The details

The DEA issued two Notices of Intent to incorporate updated concentration and ratio thresholds for these substances. The agency seeks to clearly differentiate between naturally occurring trace amounts found in botanical kratom and products with intentional, higher-level concentrations.

August 26, 2026: The DEA temporarily placed MGPI, MGM-15, and MGM-16 into Schedule I.
October 9, 2026: The Department of Justice announced the updated emergency scheduling actions.
30-day period: Current temporary scheduling controls remain in effect.

Health Landscape

This regulatory shift reflects an ongoing effort to adapt the Controlled Substances Act to evolving synthetic opioid threats. These emergency measures bridge the gap between historical drug policy and the rise of intentionally enhanced botanical derivatives.

The new thresholds clarify that trace amounts of substances found in standard botanical products are treated differently than concentrated extracts. Consumers should be aware that products intentionally enhanced beyond these federal limits may face future distribution restrictions.

The takeaway

Regulators are increasingly focused on the chemical concentration of botanical products to prevent the misuse of concentrated synthetic derivatives. Users should prioritize verifying the safety and origin of any supplements they consume.